Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes

Age-related macular degeneration

(2012) Laurence S Lim et al.   LANCET

The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology

(2012) Michael W. Stewart   MAYO CLINIC PROCEEDINGS

Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File

(2011) Ross J. Brechner et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5 mg VERSUS 3.0 mg OF BEVACIZUMAB IN HUMANS

(2011) Carsten H Meyer et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans

(2010) Carsten H. Meyer et al.   ACTA OPHTHALMOLOGICA

Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit

(2010) Moon Jung Kim et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Topical Bevacizumab in the Treatment of Corneal Neovascularization

(2009) Mohammad H. Dastjerdi   ARCHIVES OF OPHTHALMOLOGY

Topical Bevacizumab and Ocular Surface Neovascularization in Patients With Stevens-Johnson Syndrome

(2009) Harvey S Uy et al.   CORNEA

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

(2009) Yanyan Koenig et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

The Effect of Topical Bevacizumab on Corneal Neovascularization

(2008) Sang Woo Kim et al.   OPHTHALMOLOGY

Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization

(2008) Qi Zhu et al.   OPHTHALMOLOGY